Scholarlink

Background <p>Pancreatic cancer is one of the most aggressive malignancies with a 5-year relative survival rate of only 13%. Its poor prognosis is largely attributed to the lack of reliable tools for early detection. Current diagnostic standards rely on imaging methods that are invasive, costly, and often inadequate to detect early-stage disease. A noninvasive blood-based test with high sensitivity and specificity could substantially improve patient outcomes.</p> Methods <p>Lipid concentrations in plasma and serum samples were determined by ultrahigh-performance supercritical fluid chromatography–mass spectrometry, and multivariate statistical modeling was used to analyze lipid profiles and differentiate between groups.</p> Results <p>Here, we present results from a pilot study evaluating lipidomic profiling of prospectively collected plasma and serum samples from patients with pancreatic ductal adenocarcinoma (PDAC, <i>n</i> = 177), healthy controls (<i>n</i> = 218), and high-risk individuals for pancreatic cancer (<i>n</i> = 93). The lipidomic test distinguishes PDAC patients from healthy controls with an accuracy exceeding 95%, including robust detection of early-stage cases and even individuals with low CA 19-9 secretion. The sensitivity is approximately 30% higher than that of CA 19-9. In high-risk individuals, the method achieves a specificity of over 96% (95% CI, 89–99%), comparable to established imaging-based approaches.</p> Conclusions <p>This pilot study demonstrates the promising potential of lipidomic profiling as a noninvasive, blood-based screening tool for pancreatic cancer. The method outperforms current biomarkers, maintains high diagnostic accuracy in early-stage disease, and performs reliably in high-risk populations. These findings support the initiation of a clinical trial aimed at validating the lipidomic test for the early detection of PDAC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月2日

查看全文
  • Ondřej Peterka,
  • Robert Jirásko,
  • Zuzana Dolečková,
  • Mária Dosoudilová,
  • Josef Bártl,
  • Jakub Idkowiak,
  • Ondřej Slavíček,
  • Karolína Pešková,
  • Milan Vošmik,
  • Beatrice Mohelníková-Duchoňová,
  • Irena Kozubíková,
  • Martin Loveček,
  • Ondřej Urban,
  • Jan Trna,
  • Petr Karásek,
  • Bohuslav Melichar,
  • Michal Holčapek

摘要

Background

Pancreatic cancer is one of the most aggressive malignancies with a 5-year relative survival rate of only 13%. Its poor prognosis is largely attributed to the lack of reliable tools for early detection. Current diagnostic standards rely on imaging methods that are invasive, costly, and often inadequate to detect early-stage disease. A noninvasive blood-based test with high sensitivity and specificity could substantially improve patient outcomes.

Methods

Lipid concentrations in plasma and serum samples were determined by ultrahigh-performance supercritical fluid chromatography–mass spectrometry, and multivariate statistical modeling was used to analyze lipid profiles and differentiate between groups.

Results

Here, we present results from a pilot study evaluating lipidomic profiling of prospectively collected plasma and serum samples from patients with pancreatic ductal adenocarcinoma (PDAC, n = 177), healthy controls (n = 218), and high-risk individuals for pancreatic cancer (n = 93). The lipidomic test distinguishes PDAC patients from healthy controls with an accuracy exceeding 95%, including robust detection of early-stage cases and even individuals with low CA 19-9 secretion. The sensitivity is approximately 30% higher than that of CA 19-9. In high-risk individuals, the method achieves a specificity of over 96% (95% CI, 89–99%), comparable to established imaging-based approaches.

Conclusions

This pilot study demonstrates the promising potential of lipidomic profiling as a noninvasive, blood-based screening tool for pancreatic cancer. The method outperforms current biomarkers, maintains high diagnostic accuracy in early-stage disease, and performs reliably in high-risk populations. These findings support the initiation of a clinical trial aimed at validating the lipidomic test for the early detection of PDAC.